Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.18 is 29% below its 5-year average of -0.92, near the low end of its 5-year range (-1.22–-0.30).
12.38% below its 12-month average of -1.05.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.32.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 21 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.18
EARNINGS PER SHARE (EPS) AVG TTM
-1.05
EARNINGS PER SHARE (EPS) AVG 3Y
-1.11
EARNINGS PER SHARE (EPS) AVG 5Y
-0.92
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-12.38%
CURRENT VS 3Y AVG
-6.55%
CURRENT VS 5Y AVG
-28.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Design Therapeutics, Inc.
Market Cap
$747.61M
Earnings Per Share (EPS)
-1.18
TTM Avg
-1.05
3Y Avg
-1.11
5Y Avg
-0.92
Market Cap
$753.02M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.23
3Y Avg
-1.23
5Y Avg
-1.23
Market Cap
$761.37M
Earnings Per Share (EPS)
0.84
TTM Avg
0.43
3Y Avg
-11.54
5Y Avg
-7.53
Market Cap
$765.30M
Earnings Per Share (EPS)
-0.75
TTM Avg
-1.06
3Y Avg
-1.25
5Y Avg
-1.46
Market Cap
$723.18M
Earnings Per Share (EPS)
-1.41
TTM Avg
-1.23
3Y Avg
-0.97
5Y Avg
-1.16
Market Cap
$721.69M
Earnings Per Share (EPS)
-1.55
TTM Avg
-1.25
3Y Avg
-1.99
5Y Avg
-2.90
Market Cap
$776.24M
Earnings Per Share (EPS)
-0.10
TTM Avg
-0.20
3Y Avg
-0.27
5Y Avg
-0.29
Market Cap
$777.34M
Earnings Per Share (EPS)
-0.15
TTM Avg
-0.39
3Y Avg
-0.55
5Y Avg
-0.57
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $747.61M | -1.18 | -1.05 | -1.11 | -0.92 |
| Apnimed, Inc. (APMD)vs › | $742.70M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.02M | N/A | -1.23 | -1.23 | -1.23 |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.37M | 0.84 | 0.43 | -11.54 | -7.53 |
| Sana Biotechnology, Inc. (SANA)vs › | $765.30M | -0.75 | -1.06 | -1.25 | -1.46 |
| Candel Therapeutics, Inc. (CADL)vs › | $723.18M | -1.41 | -1.23 | -0.97 | -1.16 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | -1.55 | -1.25 | -1.99 | -2.90 |
| Geron Corporation (GERN)vs › | $776.24M | -0.10 | -0.20 | -0.27 | -0.29 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $777.34M | -0.15 | -0.39 | -0.55 | -0.57 |
| Varex Imaging Corporation (VREX)vs › | $778.01M | 0.52 | -1.70 | -0.56 | -0.09 |
Trailing EPS (TTM)
$-1.18
Forward EPS (Est.)
$-1.32
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.22 |
| 2024-12-31 | -0.88 |
| 2023-12-31 | -1.19 |
| 2022-12-31 | -1.14 |
| 2021-12-31 | -0.77 |
| 2020-12-31 | -0.30 |
| 2019-12-31 | -0.08 |
